Apeloa Unit Jutai Pharmaceutical Wins US FDA Approval for Brivaracetam Tablets
On September 14, 2026, Apeloa Pharmaceutical (000739) announced that its wholly owned subsidiary, Zhejiang Apeloa Jutai Pharmaceutical Co. , Ltd. , received notice from the US Food and Drug Administration that the abbreviated new drug application (ANDA) it filed with the FDA for brivaracetam tablets has been approved.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is positive for Pharmaceuticals, with intensity 50/100 and 80% confidence over a medium term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.